Abstract
We studied the effects of activate-depress-free-repeat (ADFR) treatment on bone metabolism markers in patients with involutional osteoposis.
Forty female outpatients with involutional osteoposis were divided into an ADFR treatment group (n=20) and a control group (n=20). The ADFR group was subdivided into a responder group (n=14) whose ΣGS/D increased after treatment, and a non-responder group (n=6) whose ΣGS/D decreased.
After ADFR treatment, %serum alkaline phosphatase (Alp) was significantly greater in the responders than in the non-responders (p<0.05), whereas both % urinary calcium (Ca)/creatinine (Cr) and % urinary hydroxyproline (HP)/Cr were significantly lower (p<0.05 and p<0.01, respectively). There was a significant positive correlation between % ΣGS/D and the pretreatment level of serum P(r=0.436, p<0.05) and a significant negative correlation between %ΣGS/D and the pretreatment level of urinary phosphate (P)/Cr (r=-0.455, p<0.05).
These results indicate that ADFR treatment increases % serum Alp, and decreases % urinary Ca/Cr and % urinary HP/Cr in responders. In addition, pretreatment levels of serum P and urinary P/Cr may be predictors of increased ΣGS/D after ADFR treatment.
